34825396|t|Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.
34825396|a|We report the neuropathological examination of a patient with Alzheimer's disease (AD) treated for 38 months with low doses of the BACE-1 inhibitor verubecestat. Brain examination showed small plaque size, reduced dystrophic neurites around plaques and reduced synaptic-associated Abeta compared with a group of age-matched untreated sporadic AD (SAD) cases. Our findings suggest that BACE-1 inhibition has an impact on synaptic soluble Abeta accumulation and neuritic derangement in AD.
34825396	20	27	patient	Species	9606
34825396	33	50	Alzheimer disease	Disease	MESH:D000544
34825396	77	89	verubecestat	Chemical	MESH:C000613570
34825396	140	147	patient	Species	9606
34825396	153	172	Alzheimer's disease	Disease	MESH:D000544
34825396	174	176	AD	Disease	MESH:D000544
34825396	222	228	BACE-1	Gene	23621
34825396	239	251	verubecestat	Chemical	MESH:C000613570
34825396	372	377	Abeta	Gene	351
34825396	425	436	sporadic AD	Disease	MESH:D000544
34825396	438	441	SAD	Disease	MESH:D000544
34825396	476	482	BACE-1	Gene	23621
34825396	528	533	Abeta	Gene	351
34825396	551	571	neuritic derangement	Disease	MESH:D058225
34825396	575	577	AD	Disease	MESH:D000544
34825396	Association	MESH:D000544	23621
34825396	Negative_Correlation	MESH:C000613570	23621
34825396	Association	MESH:D058225	23621
34825396	Negative_Correlation	MESH:C000613570	MESH:D000544
34825396	Association	23621	351
34825396	Association	MESH:D000544	351

